LSE •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 16:23
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeLSE
Market Capitalization77.09 mln
Float156 mln
Earnings Date08/26/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
1,002
Transformational upside
Relative Strength
2
/ 100
Severely lagging
Debt / Equity
1.55
High leverage
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Faron Pharmaceuticals, founded in 2003 and based in Turku, Finland, is a medical research company focused on developing new treatments for cancer and serious immune-related conditions. Its most advanced drug, bexmarilimab, works by reprogramming certain immune cells within tumors to help the body fight cancer more effectively, and is being tested in patients with blood cancers such as acute myeloid leukemia and myelodysplastic syndromes. The company is also researching how specific receptors in the body regulate immune responses, with potential applications in organ damage and bone marrow recovery.
